Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas

NCT06022029 is registered in ClinicalTrials.gov with OncoNano Medicine, Inc. as lead sponsor.

NCT NCT06022029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06022029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Lead sponsor
OncoNano Medicine, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 13, 2023
Completion date
August 29, 2026
Enrollment
168 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma in situ, cervix cancer, diffuse large b cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma, lymphoma, non-hodgkin, mantle cell lymphoma, metastatic cancer, skin cancer, triple negative breast cancer, tumor recurrence, tumor, solid, uveal melanoma, recurrent